Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02106507
Title ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
Recruitment Completed
Gender male
Phase Phase I
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center

prostate adenocarcinoma


Apalutamide + Everolimus

Age Groups: adult
Covered Countries USA

No variant requirements are available.